Aducanumab: A Deep Dive into BIIB037 and its Impact A medication, initially known as BIIB037, is a significant attempt to treat early-stage Alzheimer's disease. Developed by Biogen, aducanumab acts by clearing https://www.targetmol.com/compound/aducanumab